Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of tipifarnib in advanced solid tumors with HRAS mutations
NL-OMON48820Phase 2Completed
- Sponsor
- Kura Oncology
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in Nonhematologic neoplasms and cancer, sponsored by Kura Oncology. Primary endpoint: Objective response rate. Started Aug 2018; status: completed.
02
Drugs
tipifarnib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON48820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48820.